The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here.

In late 2021, Pfizer (PFE-0.21%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine. It followed that success with the launch ...

No doubt, Pfizer (PFE) is one of 2021’s out-and-out success stories. The pharma giant has posted year-to-date gains of a remarkable 72%, and the company – and investors – have Covid-19 to ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Drug giant Pfizer PFE is trading quite cheap after its stock took a beating last year once the pandemic ended. The stock is trading at a discount to the industry and is also trading below its 5 ...

Pfizer now anticipates revenue in the range of $61 billion to $64 billion and earnings per share to arrive between $2.75 to $2.95. This is higher than its previous forecast for revenue of $59.5 ...